COMMUNIQUÉS West-GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
11/08/2025
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every 3 [...]
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
11/08/2025
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe [...]
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
11/08/2025
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and [...]
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
11/08/2025
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed The company plans [...]
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
11/08/2025
Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studies Trial initially taking place in the U.S., following IND clearance Initial data expected in mid-2026 from open-label Phase 1 [...]
BioCryst Announces Departure of Dr. Helen Thackray
11/08/2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company [...]
WeightWatchers Announces Second Quarter 2025 Results
11/08/2025
Successful completion of strategic reorganization, reducing debt by $1.15 billion. In connection with emergence on 6/24/25, fiscal Q2 consists of a "Predecessor" period from 3/30/25 to 6/24/25, and a “Successor” period [...]
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
11/08/2025
JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes [...]
Kraig Biocraft Laboratories to Launch Operations at New Southeast Asia Production Facility This Week
11/08/2025
New site established in collaboration with a government agency to bolster spider silk output and market readiness ANN ARBOR, Mich., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (" [...]
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
11/08/2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release [...]
Avicanna Announces US Patent and Trademark Office Issuance of New Patent
11/08/2025
USPTO Issues Patent No. US 12,343,315 B2 covering topical cannabinoid compositions for clear skin TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: [...]
Altimmune Board of Directors Appoints Jerry Durso as Chairman
11/08/2025
Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, [...]
MediPharm Labs Sets Date to Report Second Quarter 2025 Financial Results
11/08/2025
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based [...]
CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
11/08/2025
Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which [...]
Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience
11/08/2025
MND combines proprietary resveratrol-based platform and NovaSOL ® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, [...]
Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025
11/08/2025
Revenue Increased 128% Year Over Year and 48% Sequentially FORT MILL, S.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing [...]
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
11/08/2025
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 ( [...]
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
11/08/2025
Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 [...]
ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
11/08/2025
UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be [...]

Pages